礼来旗下减重药正式在华上市 与诺和诺德厮杀激烈

中国商报
02 Jan

中国商报(记者 马嘉)1月2日,跨国药企礼来宣布, GLP-1产品替尔泊肽(商品名:穆峰达)正式在中国上市,覆盖2型糖尿病和减重两大适应证。这意味着,在国内减重药市场上,诺和诺德与礼来两大巨头将正面厮杀。减重市场两大巨头正面厮杀目前,国内已有多家电商平台供应穆峰达。礼来方面对记者表示,产品商业化上市后,公司将开始向中国各地的医药机构供应该产品。该产品是处方药,必须在专业医生监管下使用,患者应咨询...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10